GSK Stock Analysis: Buy, Sell, or Hold?
GSK - GSK plc American Depositary Shares (Each representing two Ordinary Shares)
$51.98
0.63 (1.23%)
▲
5d:
+3.88%
30d:
+0.17%
90d:
-4.52%
BUY
MODERATE Confidence
Analysis Updated: Jul 27, 2026 12:00 AM ET
Earnings: Jul 28, 2026
0d
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GSK shows positive signals but monitor for confirmation. Market pricing in 1.3% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GSK shows positive signals but monitor for confirmation. Market pricing in 1.3% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$70.96
Based on 5.5% avg growth
INTRINSIC VALUE TODAY
$44.06
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $51.98, which is considered fair relative to its 30-day fair value range of $50.93 to $52.80. The stock's valuation (Forward PE: 10.1) is in line with its historical norms (10.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.3% over the next few years. This pessimistic expectation contrasts with the company's recent 8.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GSK is in a downtrend. The price is approaching resistance at $52.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.08 (+11.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GSK is in a downtrend. The price is approaching resistance at $52.85. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.08 (+11.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$50.93 -
$52.80
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($58.08)
Trading Range Analysis
30-Day Trading Range
$50.93 -
$52.80
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$49.89
Resistance Level
$52.85
Current Trend
Downtrend
Technical data as of
Jul 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.07
Wall Street Target
$58.08
(+11.7%)
Revenue Growth (YoY)
1.5%
Earnings Growth (YoY)
8.4%
Profit Margin
17.8%
Valuation Discount vs History
-1.3% cheaper
PE vs Historical
10.1 vs 10.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.3%
(market-implied from PE analysis)
1-Year Target
$51.30
(-1%)
2-Year Target
$50.64
(-3%)
3-Year Target
$49.98
(-4%)
3-Yr Target (if PE normalizes)
(PE: 10→11)
$52.10
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.8, Growth: 7.1%)
$131.86
(+154%)
Base:
(SPY PE: 10.1, Growth: 7.1%)
$63.83
(+23%)
Bear:
(PE: 8.6, Growth: 7.1%)
$54.25
(+4%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (14x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 13.51 | Current EPS (TTM): $3.80
Bull Case
$76.71
(+48%)
Analyst growth 35.8%, PE expands to 14.9
Base Case
$69.73
(+34%)
Market implied 35.8%, PE stable at 13.5
Bear Case
$34.92
(-33%)
Severe decline -20.0%, PE contracts to 11.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.1 to 10.5
Stabilization Target:
$54.18
(+4.2%)
PE Expansion Potential:
+4.2%
Share & Embed Analysis
Last updated: July 27, 2026 9:19 PM ET
Data refreshes hourly during market hours. Next update: 10:19 PM
Data refreshes hourly during market hours. Next update: 10:19 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1270 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$158 | 55 HOLD |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$268 | 56 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$228 | 54 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$357 | 52 HOLD |
